An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT02576509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Study identification
- NCT ID
- NCT02576509
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 743 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2015 (Actual)
- Primary completion
- May 30, 2019 (Actual)
- Completion
- Feb 7, 2024 (Actual)
- Last update posted
- Feb 17, 2025
2015 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0066 | Birmingham | Alabama | 35294 | — |
| Local Institution - 0020 | Los Angeles | California | 90095 | — |
| Local Institution - 0015 | San Francisco | California | 94115 | — |
| Local Institution - 0084 | San Francisco | California | 94143 | — |
| Local Institution - 0061 | Chicago | Illinois | 60637 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Local Institution - 0083 | New York | New York | 10029 | — |
| Local Institution - 0093 | New York | New York | 10065 | — |
| Local Institution - 0016 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0095 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0019 | Philadelphia | Pennsylvania | 19107 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Local Institution - 0017 | San Antonio | Texas | 78229 | — |
| Scott & White Memorial Hospital And Clinic | Temple | Texas | 76508 | — |
| Local Institution - 0026 | Seattle | Washington | 98101 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Local Institution - 0050 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02576509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02576509 live on ClinicalTrials.gov.